Cat. No. | Especies | Descripción del producto | Estructura | Pureza | Característica |
---|---|---|---|---|---|
DL4-H82F7 | Human | Biotinylated Human DLL4 Protein, Fc,Avitag™, premium grade | ![]() |
![]() ![]() |
|
DL4-H5255 | Human | Human DLL4 Protein, Fc Tag, premium grade | ![]() |
![]() ![]() |
|
RES-A022 | Human | resDetect™ Biotinylated Human DLL4 ELISA Kit (Residue Testing) | |||
RES-A052 | Human | resDetect™ Human Fc Tag DLL4 ELISA KIT (Residue Testing) | |||
GMP-DL4H28 | Human | GMP Human DLL4 Protein, Fc Tag | ![]() |
![]() ![]() |
|
GMP-DL4H23 | Human | GMP Biotinylated Human DLL4 Protein, His,Avitag™ | ![]() |
![]() ![]() |
|
MBS-C013 | Human | ActiveMax® Human DLL4 μBeads, premium grade (for cells) | |||
CEA-B038 | Human | ClinMax™ Human Soluble Delta Like Protein 4 (DLL4) ELISA Kit, PRO | |||
DL4-H82E6 | Human | Biotinylated Human DLL4 Protein, His,Avitag™, premium grade | ![]() |
![]() ![]() |
|
DL4-H5227 | Human | Human DLL4 Protein, His Tag | ![]() |
![]() ![]() |
|
DL4-H5259 | Human | Human DLL4 Protein, Fc Tag (MALS & SPR verified) | ![]() |
![]() ![]() |
Biotinylated Human DLL4 Protein, Fc, Avitag, premium grade (Cat. No. DL4-H82F7) stimulates Human Notch1 (Luc) HeLa Reporter Cell. The EC50 of the effect is 7.10 µg/mL (Routinely tested).
Human DLL4 Protein, Fc Tag, premium grade (Cat. No. DL4-H5255) captured on Protein A Chip can bind Human NOTCH1 Protein, His Tag, premium grade (Cat. No. NO1-H52H3) with an affinity constant between 1.00 nM - 150 nM as determined in a SPR assay (Biacore 8K) (QC tested).
GMP Human DLL4 Protein, Fc Tag (Cat. No. GMP-DL4H28) captured on Protein A Chip can bind Human NOTCH1 Protein, His Tag, premium grade (Cat. No. NO1-H52H3) with an affinity constant between 1.00 nM - 150 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
TR-009 | NOV-1501; ABL001-ABL Bio; CTX-009; HD-B001A; ABL-001-ABL Bio; HDB001A; TR-009; ES-104 | Phase 3 Clinical | Abl Bio Inc | Biliary Tract Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Bile Duct Neoplasms; Ampullary Carcinoma; Gallbladder Neoplasms | Details |
Navicixizumab | OMP-305B83 | Phase 3 Clinical | Oncomed Pharmaceuticals Inc | Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms | Details |
Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.